Pyxis Oncology’s (PYXS) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report published on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has a $8.00 target price on the stock.

Other equities analysts also recently issued reports about the stock. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Stock Up 8.0 %

NASDAQ PYXS opened at $1.21 on Wednesday. The company has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The stock’s 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $2.36. Pyxis Oncology has a twelve month low of $0.99 and a twelve month high of $6.18.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter. On average, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently added to or reduced their stakes in PYXS. MetLife Investment Management LLC lifted its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the period. Bank of America Corp DE grew its holdings in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after acquiring an additional 10,000 shares during the last quarter. Barclays PLC increased its position in Pyxis Oncology by 20.2% during the fourth quarter. Barclays PLC now owns 77,013 shares of the company’s stock valued at $121,000 after acquiring an additional 12,924 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after buying an additional 14,349 shares during the period. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.